Patents by Inventor Rene Holm

Rene Holm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE
    Publication number: 20240091223
    Abstract: The present invention relates to a pharmaceutical composition comprising the calcium; {4-[(5,6-diphenylpyrazin-2-yl) (propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process to produce it.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 21, 2024
    Inventors: Katie AMSSOMS, Eddy DE PROOST, Wenyu DONG, Paul HARTMAN KOK, Rene HOLM, Kristof KIMPE, Greet MEURS, Maxim VERSTRAETEN
  • TREATMENT OR PREVENTION OF A DISEASE OR DISORDER
    Publication number: 20230405094
    Abstract: The present invention relates to the treatment or prevention of a disease or disorder using a drug in the form of micro- or nanoparticles in suspension, in combination with a hyaluronidase.
    Type: Application
    Filed: November 17, 2021
    Publication date: December 21, 2023
    Inventors: René Holm, Steven M. Vesole, Guenter Karl Wilhelm Kraus
  • TREATMENT OR PREVENTION OF HIV INFECTION
    Publication number: 20230405001
    Abstract: The present invention relates to the treatment or prevention of HIV infection using rilpivirine or a pharmaceutically acceptable salt thereof in the form of micro- or nanoparticles in suspension in combination with a hyaluronidase. The present invention also relates to rilpivirine or a pharmaceutically acceptable salt thereof in the form of micro- or nanoparticles in suspension.
    Type: Application
    Filed: November 17, 2021
    Publication date: December 21, 2023
    Inventors: Steven M. Vesole, Guenter Karl Wilhelm Kraus, Herta Maria Ludovica Crauwels, René Holm, Nico Rudolph Niemeijer, Iwan Caroline F. Vervoort
  • LONG-ACTING FORMULATIONS
    Publication number: 20230355606
    Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and comprising a poloxamer as a surface modifier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 9, 2023
    Inventors: René HOLM, Iwan Caroline F. VERVOORT
  • PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID
    Publication number: 20230310413
    Abstract: Described herein are pharmaceutical formulations comprising a MALT1 inhibitor and a mixture comprising fatty acid and polyethylene glycol monoesters and diesters, and optionally, fatty acid and glycerol monoesters, diesters and triesters. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of treatment are also described.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 5, 2023
    Inventors: Sanket Manoj SHAH, Donghua ZHU, René HOLM, Kristof Leonard KIMPE
  • LONG-ACTING FORMULATIONS
    Publication number: 20230241051
    Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and comprising PEG4000 as a surface modifier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 3, 2023
    Inventors: René HOLM, Iwan Caroline F. VERVOORT, Wenyu DONG, Miriam COLOMBO
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20230021520
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 26, 2023
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
  • 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
    Patent number: 11458134
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 4, 2022
    Assignee: H. Lundbeck A/S
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20220175760
    Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient, a polyethylene glycol having a freezing point of at least about 30° C., and a crystallisation rate inhibitor. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of treatment are also described.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 9, 2022
    Inventors: Kristof Leonard KIMPE, Sanket Manoj SHAH, Audrey Antoinette Renee LATHUILE, Rene HOLM, Thomas Eddy R NEEFS, Hana PROKOPCOVA
  • Vortioxetine pyroglutamate
    Patent number: 11279682
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 22, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20200163959
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: July 3, 2019
    Publication date: May 28, 2020
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIB
    Publication number: 20190381174
    Abstract: Disclosed are formulations/compositions comprising ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 19, 2019
    Inventors: Maristella Bernini, Wenyu Dong, Rene Holm
  • Vortioxetine Pyroglutamate
    Publication number: 20190210987
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt
    Type: Application
    Filed: March 6, 2019
    Publication date: July 11, 2019
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • Vortioxetine pyroglutamate
    Patent number: 10287261
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: May 14, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20180333408
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 22, 2018
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9861630
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 9, 2018
    Assignee: H. Lundbeck A/S
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20170360777
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: August 10, 2017
    Publication date: December 21, 2017
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
    Patent number: 9610287
    Abstract: The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: April 4, 2017
    Assignee: H. Lundbeck A/S
    Inventors: René Holm, Lone Bruun
  • Vortioxetine Pyroglutamate
    Publication number: 20160368884
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 22, 2016
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20160083359
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 24, 2016
    Inventors: Benny Bang-Andersen, André Faldt, Arne Mørk, Heidi Lopez De Diego, René Holm, Tine Bryan Stensbøl, Lone Munch Ringgard, Michael J. Mealy, Michael Harold Rock, Jørgen Brodersen, Morten Jørgensen, Nicholas Moore